(NASDAQ: CDTX) Cidara Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 9.68%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.82%.
Cidara Therapeutics's earnings in 2025 is -$182,981,000.On average, 2 Wall Street analysts forecast CDTX's earnings for 2025 to be -$91,048,157, with the lowest CDTX earnings forecast at -$98,700,353, and the highest CDTX earnings forecast at -$83,395,962. On average, 2 Wall Street analysts forecast CDTX's earnings for 2026 to be -$103,434,338, with the lowest CDTX earnings forecast at -$128,660,644, and the highest CDTX earnings forecast at -$78,208,033.
In 2027, CDTX is forecast to generate -$104,796,170 in earnings, with the lowest earnings forecast at -$124,899,395 and the highest earnings forecast at -$84,692,944.